Core Points - Windtree Therapeutics, Inc. has announced a 1-for-50 reverse stock split approved by its board of directors and stockholders to comply with Nasdaq's minimum bid price requirement [1][2] - The reverse stock split will take effect on February 20, 2025, and trading on a reverse-adjusted basis will begin on February 21, 2025 [2] - Post-split, the number of outstanding shares will be reduced to approximately 700,000, with no fractional shares issued [4] Company Overview - Windtree Therapeutics is a biotechnology company focused on developing innovative therapies for critical conditions and diseases, including a Phase 2 candidate for acute heart failure [7] - The company has a licensing business model with existing partnership out-licenses [7]

Core Insights - Windtree Therapeutics, Inc. announced a positive presentation on istaroxime at the Technology and Heart Failure Therapeutics Conference, highlighting its potential in treating early cardiogenic shock [1][2] Company Overview - Windtree Therapeutics is a biotechnology company focused on innovative therapies for critical conditions, with a portfolio that includes istaroxime, which is in Phase 2 trials for acute heart failure and cardiogenic shock [5] Istaroxime Details - Istaroxime is a first-in-class dual-mechanism therapy designed to improve both systolic and diastolic cardiac function, enhancing myocardial contractility and facilitating myocardial relaxation [4] - The therapy has shown significant improvements in cardiac function and blood pressure in multiple Phase 2 studies without increasing heart rate or causing cardiac rhythm disturbances [4] Clinical Development - The company is prioritizing cardiogenic shock as an initial indication for istaroxime due to its unique profile and the positive outcomes from Phase 2 studies [3] - There is a substantial unmet need in treating early cardiogenic shock, as existing treatments often have undesirable side effects and poor outcomes [3]

Core Insights - Windtree Therapeutics, Inc. has announced the issuance of a patent in Japan for aPKCi inhibitors aimed at treating hedgehog pathway-dependent cancers, with the patent number 7603605 expiring in 2040 [1][2][3] Company Overview - Windtree Therapeutics is a biotechnology company focused on developing innovative therapies for critical conditions and diseases, with a portfolio that includes istaroxime for acute heart failure and preclinical aPKCi inhibitors for oncology applications [4] Product Development - The aPKCi inhibitor platform is a high-potency drug candidate with applications in treating various cancers, including basal cell carcinoma and small cell lung cancer, and includes both topical and oral formulations developed in collaboration with Cancer Research UK [2][3] - The company is also pursuing additional patent applications for crystalline forms of aPKCi inhibitors for cancer treatment [3] Strategic Direction - The issuance of the new patent is a significant part of the company's development strategy, with plans to expand its intellectual property portfolio in key global markets [3]

The Company’s oncology aPKCi inhibitor is a novel, first in class drug candidateWARRINGTON, Pa., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced the issuance of a patent in Japan for “Inhibitors of atypical protein kinase C (aPKCi) and their use in treating hedgehog pathway-dependent cancers.” The patent num ...

Industry leaders deliver comprehensive distribution of AI-based water management, protection and risk mitigation solutions throughout the U.S.NEW YORK, Jan. 14, 2025 /PRNewswire/ -- WINT Water Intelligence, a global leader in cutting-edge water management and leak-prevention solutions, announces a strategic collaboration with Ferguson, the largest value-added distributor of plumbing supplies, PVF, waterworks, and fire and fabrication products in the United States. WINT's solutions are now available to Fergu ...

WARRINGTON, Pa., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced the appointment of Leanne Kelly to its board of directors (“Board”). Ms. Kelly has significant public company executive experience and joins the Board as an independent director and chair of the audit committee. Ms. Kelly has served as GRI Bio’ ...

WARRINGTON, Pa., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced it has launched a new corporate strategy to become a revenue generating biotech company through acquisitions of small companies and their FDA-approved products while the Company continues to progress its cardiovascular and oncology development ...

WARRINGTON, Pa., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced that Alexandre Mebazaa, MD, one of the world’s recognized leaders in cardiogenic shock, gave a well-received presentation highlighting the data on istaroxime from the recently completed Phase 2b SEISMiC B study in early cardiogenic shock due to ...

WARRINGTON, Pa., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced that it has engaged New Growth Advisors (“NGA”), a leading life sciences consulting firm chosen by companies seeking discreet, conflict-free, and knowledgeable advice on complex M&A, asset sale, research, capital markets, and licensing transact ...

Exhibit 99.1 Windtree Therapeutics Reports Third Quarter 2024 Financial Results and Provides Key Business Updates WARRINGTON, PA – November 27, 2024 – Windtree Therapeutics, Inc. ("Windtree" or "the Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the third quarter ended September 30, 2024 and provided key business updates. "The third quarter of 2024 was marked with significant pro ...